Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70224 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Jia-Ling Wu and 8 co-authors. Institution: Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan. Major MEDLINE topics: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis B. Cited 5 times so far (Crossref); 27 references. Funded by: E-Da Hospital, Gilead Sciences.
Abstract (original language)
Background
Deaths from hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) are projected to increase through 2030. Underutilisation of antiviral therapy may contribute to this concerning trend but empirical data remain sparse.
Aims
We aimed to assess the frequency of missed opportunities for antiviral therapy before HBV‐related HCC development and to investigate factors associated with non‐treatment.
Methods
We analysed the electronic medical records from a large healthcare group in Taiwan to identify all HBV‐infected patients who developed HCC between 1 April 2004 and 24 May 2022. HBV infection was confirmed by hepatitis B surface antigen seropositivity and incident HCC was verified through the cancer registry. Patients were grouped based on whether they had received antiviral therapy prior to the HCC diagnosis.
Results
Among 1017 patients with HBV‐related HCC (median age, 60.8 years; 80.1% male; 42.9% with cirrhosis), 75% had not received antiviral therapy before developing HCC. Compared to treated patients, the untreated group had a significantly lower proportion of cirrhosis (33.5% vs. 71.0%), higher platelet counts, elevated liver enzyme levels, and higher viral loads. They also had significantly fewer specialist visits (median frequency, 0.3 vs. 3.6 visits per year) and biomarker evaluations, and were less frequently diagnosed at early stages (Stage I/II, 49.5% vs. 81.6%) with a significantly shorter median survival (2.1 vs. 4.4 years).
Conclusion
Three‐quarters of patients who developed HBV‐related HCC had not received antiviral therapy before HCC diagnosis. These patients were characterised by a lower proportion of cirrhosis, infrequent clinical visits, fewer HBV evaluations, more advanced HCC stage, and poorer prognosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
- Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
- Administrative Center, E-Da Healthcare System, Kaohsiung, Taiwan.
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
ORCID profiles: Ying-Nan Tsai, Cheng-Hao Tseng, Chih-Wen Lin, Mindie H Nguyen, Yao-Chun Hsu
Funding
- E-Da Hospital
- Gilead Sciences
Cite
APA
Wu, J. L., Tsai, Y. N., Tseng, C. H., Tseng, S. C., Lin, C. W., Hung, C. L., Nguyen, M. H., Lin, J. T., & Hsu, Y. C. (2025). Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70224
Vancouver
Wu JL, Tsai YN, Tseng CH, Tseng SC, Lin CW, Hung CL, et al. Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70224
BibTeX
@article{Wu2025,
author = {Wu, Jia-Ling and Tsai, Ying-Nan and Tseng, Cheng-Hao and Tseng, Shang-Chen and Lin, Chih-Wen and Hung, Chih-Lung and Nguyen, Mindie H and Lin, Jaw-Town and Hsu, Yao-Chun},
title = {Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70224}
}
EUVIMED